|Description||AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellent HWB potency (HWB (pAKT) IC50 = 2.7 nM). AM-8508 inhibits KLH-specific antibodies in animal models and it may become a drug candidate for the treatment of human inflammatory diseases.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...
AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellen...
Copanlisib, also known as BAY 80-6946, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activat...
CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrat...
MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.
ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a pote...
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
SF2523 is a dual inhibitor of phosphatidylinositol 3-kinase and bromodomain-containing protein 4 with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for ...
Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved t...
PIK-294 is a potent PI3K inhibitor.
CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...
PIK-93 is a potent PI3K inhibitor.
Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor...
TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...
PI3Ky inhibitor 1
PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.
GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...
BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...
PQR309, a pan inhibitor of phosphoinositide-3-kinases, is still under Phase II clinical trial against Glioblastoma and Lymphoma.
Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms o...
ON 146040 was highly potent in killing hematologic tumor cells with IC50 values in the 150 to 1,000 nM range. In biochemical testing, ON 146040 inhibited PI3K α...